Key result
Inhibitors of the platelet glycoprotein IIb/IIIa receptor profoundly inhibit arterial thrombosis and have the potential to effectively treat heparin-resistant intracoronary thrombosis.
Population
Patients with coronary artery disease and acute coronary thrombosis
Design
Review
Authors
Loading...
Hypothesis-generating for GPIIb/IIIa inhibitors in heparin-resistant thrombosis; randomized trials needed before clinical adoption.
GPIIb/IIIa receptor antagonists represent a significant advancement in antiplatelet therapy for coronary artery disease, particularly in interventional cardiology.
TIMMIS et al. (1997) conducted a review in Coronary Artery Disease. GPIIb/IIIa Receptor Antagonists was evaluated. Inhibitors of the platelet glycoprotein IIb/IIIa receptor profoundly inhibit arterial thrombosis and have the potential to effectively treat heparin-resistant intracoronary thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: